July 6, 2026 · Form 4 insider transaction
Boulding Mark Elliott sold 2,226 shares of PTC Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.; This option was granted on January 5, 2023 and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.